To include your compound in the COVID-19 Resource Center, submit it here.

TPG, Vida back Asklepios in $235M round

TPG Capital and Vida Ventures have again teamed up to invest in a biotech's megaround, pouring a combined $225 million into gene therapy company Asklepios in exchange for a undisclosed minority stake. The company's founders and board members

Read the full 383 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers